Dyne Therapeutics (DYN) Change in Accured Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Change in Accured Expenses data on file, last reported at -$4.8 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 44.15% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was $12.0 million, a 7.55% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 192.14% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.8 million, up from -$9.5 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for DYN reached as high as $21.4 million in Q4 2023 and fell as low as -$28.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $954529.4 across 5 years, with a median of -$991000.0 in 2024.
• Across the five-year window, Change in Accured Expenses jumped 917.29% in 2023 and plunged 854.89% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $4.6 million in 2022, then soared by 360.85% to $21.4 million in 2023, then tumbled by 104.63% to -$991000.0 in 2024, then plunged by 854.89% to -$9.5 million in 2025, then surged by 49.23% to -$4.8 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.8 million in Q1 2026, -$9.5 million in Q4 2025, and $18.5 million in Q3 2025.